The Journal also features annotations reviews short reports images in haematology and Letters to the Editor.
Mylotarg is a humanized anti-CD33calicheamicin conjugate developed for targeted treatment of AML and was approved for use by the US Food and Drug Administration in 2000 but withdrawn in October 2010 because of concerns about both toxicity and efficacy in adults.
60-70 of patients recover spontaneously 3 months after diagnosis transient ITP whereas 10-20 remain thrombocytopenic beyond 12 months chronic ITP.
The Journal also features annotations reviews short reports images in haematology and Letters to the Editor.
From July 1984 the five Nordic countries Denmark Finland Iceland Norway and Sweden have registered all children with acute myeloid leukaemia AML and treated them on two consecutive protocols of different intensity NOPHO-84 and NOPHO-88.
L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia ALL.
60-70 of patients recover spontaneously 3 months after diagnosis transient ITP whereas 10-20 remain thrombocytopenic beyond 12 months chronic ITP.
The British Journal of Haematology publishes original research papers in clinical laboratory and experimental haematology.
L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia ALL.
The Journal also features annotations reviews short reports images in haematology and Letters to the Editor.
Background Newly diagnosed childhood immune thrombocytopenia ITP an acquired autoimmune bleeding disease has a good prognosis.
The t712q36p13 MNX1ETV6 is not included in the WHO classification but has been described in up to 30 of acute myeloid leukemia AML in children.
The British Journal of Haematology publishes original research papers in clinical laboratory and experimental haematology.
Background Newly diagnosed childhood immune thrombocytopenia ITP an acquired autoimmune bleeding disease has a good prognosis.
The Journal also features annotations reviews short reports images in haematology and Letters to the Editor.
The ALL-2008 protocol is a treatment and research protocol that aims to improve the overall outcome of Nordic children and adolescents with ALL in comparison with the ALL-2000 protocol and previous NOPHO protocols.
The Journal also features annotations reviews short reports images in haematology and Letters to the Editor.
Mylotarg is a humanized anti-CD33calicheamicin conjugate developed for targeted treatment of AML and was approved for use by the US Food and Drug Administration in 2000 but withdrawn in October 2010 because of concerns about both toxicity and efficacy in adults.
The t712q36p13 MNX1ETV6 is not included in the WHO classification but has been described in up to 30 of acute myeloid leukemia AML in children.
60-70 of patients recover spontaneously 3 months after diagnosis transient ITP whereas 10-20 remain thrombocytopenic beyond 12 months chronic ITP.
The ALL-2008 protocol is a treatment and research protocol that aims to improve the overall outcome of Nordic children and adolescents with ALL in comparison with the ALL-2000 protocol and previous NOPHO protocols.
The t712q36p13 MNX1ETV6 is not included in the WHO classification but has been described in up to 30 of acute myeloid leukemia AML in children.
L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia ALL.
The British Journal of Haematology publishes original research papers in clinical laboratory and experimental haematology.
The Journal also features annotations reviews short reports images in haematology and Letters to the Editor.
Clinical course presentation re-exposure to L-asparginase after pancreatitis and risk of recurrent pancreatitis with.
Mylotarg is a humanized anti-CD33calicheamicin conjugate developed for targeted treatment of AML and was approved for use by the US Food and Drug Administration in 2000 but withdrawn in October 2010 because of concerns about both toxicity and efficacy in adults.
The t712q36p13 MNX1ETV6 is not included in the WHO classification but has been described in up to 30 of acute myeloid leukemia AML in children.
The British Journal of Haematology publishes original research papers in clinical laboratory and experimental haematology.
The ALL-2008 protocol is a treatment and research protocol that aims to improve the overall outcome of Nordic children and adolescents with ALL in comparison with the ALL-2000 protocol and previous NOPHO protocols.
The Journal also features annotations reviews short reports images in haematology and Letters to the Editor.
Mylotarg is a humanized anti-CD33calicheamicin conjugate developed for targeted treatment of AML and was approved for use by the US Food and Drug Administration in 2000 but withdrawn in October 2010 because of concerns about both toxicity and efficacy in adults.
The t712q36p13 MNX1ETV6 is not included in the WHO classification but has been described in up to 30 of acute myeloid leukemia AML in children.
